Success Metrics

Active Trials
8(89%)

Phase Distribution

Ph phase_2
5
56%
Ph early_phase_1
1
11%
Ph phase_1
3
33%

Phase Distribution

4

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

8

trials recruiting

Total Trials

9

all time

Status Distribution
Active(9)

Detailed Status

Recruiting8
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
8
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (11.1%)
Phase 13 (33.3%)
Phase 25 (55.6%)

Trials by Status

recruiting889%
not_yet_recruiting111%

Recent Activity

8 active trials
Showing 5 of 9
recruitingphase_2

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

NCT07283705
recruitingphase_1

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

NCT07532902
recruitingphase_1

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

NCT06672523
recruitingphase_2

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121
not_yet_recruitingphase_2

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT07492680
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07283705Phase 2

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Recruiting
NCT07532902Phase 1

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Recruiting
NCT06672523Phase 1

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Recruiting
NCT07076121Phase 2

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Recruiting
NCT07492680Phase 2

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not Yet Recruiting
NCT06855771Phase 2

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Recruiting
NCT07063745Phase 2

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Recruiting
NCT07077434Phase 1

A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors

Recruiting
NCT06883747Early Phase 1

Clinical Trial of BMS-986504 in Recurrent GBM Patients

Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9